Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine

被引:110
作者
Marcovina, Santica M.
Sirtori, Cesare
Peracino, Andrea
Gheorghiade, Mihai
Borum, Peggy
Remuzzi, Giuseppe
Ardehali, Hossein
机构
[1] Univ Washington, Dept Med, Seattle, WA USA
[2] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy
[3] Giovanni Lorenzini Med Sci Fdn, Milan, Italy
[4] Northwestern Univ, Ctr Cardiovasc Innovat, Feinberg Sch Med, Chicago, IL 60611 USA
[5] Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL 32611 USA
[6] Mario Negri Inst Pharmacol Res, Milan, Italy
[7] Dept Med & Transplantat, Bergamo, Italy
[8] Northwestern Univ, Feinberg Cardiovasc Res Inst, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
ACETYL-L-CARNITINE; TYPE-2; DIABETES-MELLITUS; FATTY-ACID OXIDATION; MUSCLE INSULIN-RESISTANCE; HEART-FAILURE SYNDROMES; SKELETAL-MUSCLE; NITRIC-OXIDE; LIPOIC ACID; GLUCOSE DISPOSAL; COENZYME-A;
D O I
10.1016/j.trsl.2012.10.006
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Mitochondria play important roles in human physiological processes, and therefore, their dysfunction can lead to a constellation of metabolic and non metabolic abnormalities such as a defect in mitochondrial gene expression, imbalance in fuel and energy homeostasis, impairment in oxidative phosphorylation, enhancement of insulin resistance, and abnormalities in fatty acid metabolism. As a consequence, mitochondrial dysfunction contributes to the pathophysiology of insulin resistance, obesity, diabetes, vascular disease, and chronic heart failure. The increased knowledge on mitochondria and their role in cellular metabolism is providing new evidence that these disorders may benefit from mitochondrial-targeted therapies. We review the current knowledge of the contribution of mitochondrial dysfunction to chronic diseases, the outcomes of experimental studies on mitochondrial-targeted therapies, and explore the potential of metabolic modulators in the treatment of selected chronic conditions. As an example of such modulators, we evaluate the efficacy of the administration of L-carnitine and its analogues acetyl and propionyl L-carnitine in several chronic diseases. L-carnitine is intrinsically involved in mitochondrial metabolism and function as it plays a key role in fatty acid oxidation and energy metabolism. In addition to the transportation of free fatty acids across the inner mitochondria! membrane, L-carnitine modulates their oxidation rate and is involved in the regulation of vital cellular functions such as apoptosis. Thus, L-carnitine and its derivatives show promise in the treatment of chronic conditions and diseases associated with mitochondrial dysfunction but further translational studies are needed to fully explore their potential. (Translational Research 2013;161:73-84)
引用
收藏
页码:73 / 84
页数:12
相关论文
共 102 条
[21]   Mitochondrial dysfunction and insulin resistance from the outside in: extracellular matrix, the cytoskeleton, and mitochondria [J].
Coletta, Dawn K. ;
Mandarino, Lawrence J. .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2011, 301 (05) :E749-E755
[22]   Diabetic cardiomyopathy-associated dysfunction in spatially distinct mitochondrial subpopulations [J].
Dabkowski, Erinne R. ;
Williamson, Courtney L. ;
Bukowski, Valerie C. ;
Chapman, Rebecca S. ;
Leonard, Stephen S. ;
Peer, Cody J. ;
Callery, Patrick S. ;
Hollander, John M. .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2009, 296 (02) :H359-H369
[23]   Pathogenesis of type 2 diabetes mellitus [J].
DeFronzo, RA .
MEDICAL CLINICS OF NORTH AMERICA, 2004, 88 (04) :787-+
[24]   RELATIONSHIP BETWEEN OXIDATIVE-PHOSPHORYLATION AND ADENINE-NUCLEOTIDE TRANSLOCASE ACTIVITY OF 2 POPULATIONS OF CARDIAC MITOCHONDRIA AND MECHANICAL RECOVERY OF ISCHEMIC HEARTS FOLLOWING REPERFUSION [J].
DUAN, JM ;
KARMAZYN, M .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1989, 67 (07) :704-709
[25]   Obesity-associated insulin resistance in skeletal muscle: Role of lipid accumulation and physical inactivity [J].
Eckardt, Kristin ;
Taube, Annika ;
Eckel, Juergen .
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2011, 12 (03) :163-172
[26]   The metabolic syndrome [J].
Eckel, Robert H. ;
Alberti, K. G. M. M. ;
Grundy, Scott M. ;
Zimmet, Paul Z. .
LANCET, 2010, 375 (9710) :181-183
[27]   Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production [J].
EL Midaoui, A ;
Elimadi, A ;
Wu, LY ;
Haddad, PS ;
de Champlain, J .
AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (03) :173-179
[28]  
Erqou S, 2009, JAMA-J AM MED ASSOC, V302, P412, DOI 10.1001/jama.2009.1063
[29]   Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes Lessons Learned and Directions Forward [J].
Felker, G. Michael ;
Pang, Peter S. ;
Adams, Kirkwood F. ;
Cleland, John G. F. ;
Cotter, Gad ;
Dickstein, Kenneth ;
Filippatos, Gerasimos S. ;
Fonarow, Gregg C. ;
Greenberg, Barry H. ;
Hernandez, Adrian F. ;
Khan, Sadiya ;
Komajda, Michel ;
Konstam, Marvin A. ;
Liu, Peter P. ;
Maggioni, Aldo P. ;
Massie, Barry M. ;
McMurray, John J. ;
Mehra, Mandeep ;
Metra, Marco ;
O'Connell, John ;
O'Connor, Christopher M. ;
Pina, Ileana L. ;
Ponikowski, Piotr ;
Sabbah, Hani N. ;
Teerlink, John R. ;
Udelson, James E. ;
Yancy, Clyde W. ;
Zannad, Faiez ;
Gheorghiade, Mihai .
CIRCULATION-HEART FAILURE, 2010, 3 (02) :314-325
[30]   Insulin resistance, hyperinsulinemia, and blood pressure - Role of age and obesity [J].
Ferrannini, E ;
Natali, A ;
Capaldo, B ;
Lehtovirta, M ;
Jacob, S ;
YkiJarvinen, H ;
BeckNielsen, H ;
Bell, P ;
Bonora, E ;
CavalloPerin, P ;
DelPrato, S ;
Fliser, D ;
Golay, A ;
Groop, LC ;
Laakso, M ;
Lalic, N ;
Mingrone, G ;
Mitrakou, A ;
Paolisso, G ;
Rett, K ;
Smith, U ;
Weck, M .
HYPERTENSION, 1997, 30 (05) :1144-1149